USDA Report Shows Major Decline For Hemp Industry In 2022, With Stakeholders Blaming FDA ‘Inaction’ On CBD

April 24, 2023 · marijuanamoment.net

The hemp industry took a major plunge in 2022, a new report from the U.S. Department of Agriculture (USDA) shows, and stakeholders say the Food and Drug Administration’s (FDA) refusal to issue regulations for CBD products is largely to blame.

USDA’s National Hemp Report shows significant losses in the value and cultivation of the non-intoxicating cannabis crop across every metric that it analyzed for 2022.

Last year, “the value of hemp production in the open and under protection for the United States totaled $238 million, down 71 percent from 2021,” the report says.

Farmers grew 28,314 acres of industrial hemp in the open last year, which is nearly 50 percent lower than the prior year.

Floral hemp production fell 66 percent, grain hemp dropped 44 percent, fiber hemp declined by 34 percent, seed hemp plummeted 92 percent and hemp clones/transplants were down 94 percent.

The data is the result of a survey that USDA mailed to thousands of hemp farmers across the U.S. in January.

The first version of the department’s hemp report was released early last year, setting a “benchmark” to compare to as the industry matures. Across the board, the market declined in the year since, which stakeholders attribute FDA’s “inaction” on creating regulations for hemp-derived cannabinoids like CBD.

Without an FDA-approved way to market CBD as dietary supplements or in the food supply, hemp growers producing the crop for its flower have been stuck in a holding pattern, unable to fully profit from what has historically been the most lucrative component of the plant.

USDA’s new report doesn’t provide commentary or analysis about the reason for the abrupt industry drop-off.

But Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said in an email blast that the report “makes clear what has been evident in the industry for years: The economic opportunity for U.S. farmers continues to decline, with the chief culprit being FDA’s inaction on regulating hemp extracts such as CBD.”

FDA said in January that, after years of review since hemp and its derivatives like CBD were legalized under the 2018 Farm Bill, it determined that there is not a regulatory pathway in place to enact rules allowing the non-intoxicating cannabinoid to be marketed as a food item or dietary supplement. It said that congressional action is required to develop CBD regulations.

Rep. James Comer (R-KY), chair of the House Oversight and Accountability Committee, sent a letter to FDA Commissioner Robert Califf last week, announcing an investigation into the agency’s decision and criticizing the “insufficient rationale for inaction” on CBD regulations.

“It’s time to regulate CBD now,” Miller said, adding that Congress should work to enact recently filed bipartisan legislation from Reps. Morgan Griffith (R-VA) and Angie Craig (D-MN) to provide a pathway for the regulation of hemp derivatives like CBD as dietary supplements and food and beverage additives.

Griffith and Rep. Brett Guthrie (R-KY) sent a letter to Califf last year, demanding answers over the continued lack of regulations for CBD for those purposes.

Griffith and other bipartisan lawmakers sent a separate, related letter to the FDA commissioner in August. They expressed frustration over the “completely insufficient response” the agency provided in response to their bill calling for hemp-derived CBD to be permitted and regulated as a food additive.

FDA’s announcement that it wouldn’t be regulating CBD came days after the agency released finalized guidance that focuses on developing cannabis-based drugs and outlined the process and unique considerations for scientists when it comes to hemp and marijuana.

All of this comes in the background of a major task for FDA: Conducting a scientific review into marijuana, at the direction of President Joe Biden, to aid in an assessment of its federal scheduling. FDA’s recommendation won’t be binding, but officials say they expect the Drug Enforcement Administration (DEA) to produce a scheduling recommendation that’s consistent with their findings about its risks and benefits.

Meanwhile, USDA announced in January that it was launching a weekly newsletter to provide “unbiased, timely, and accurate data” on the hemp industry. (Full Story)

In categories:CBD Hemp
Next Post

UK-based CBD brand Naturecan acquires Oregon production facility

United Kingdom-based CBD and wellness brand Naturecan acquired the IAH Oregon cannabidiol production facility in the U.S. for 8 million pounds (roughly $10 million). Naturecan did not specify how it would satisfy the price of the acquisition. IAH Oregon, headquartered…
Read
Previous Post

Report: Hemp Production in West Virginia Nosedives

Cultivation of industrial hemp in the open in West Virginia fell nearly 50% from 2021 to 2022, according to U.S. Department of Agriculture (USDA) data outlined by WBOY. In all, there were 65 acres of hemp planted in the open in…
Read
Random Post

Mexican Senator To File Psychedelics Legalization Bill, With U.S. Congressman Backing International Reform Push

A Mexican senator announced on Wednesday that she will be introducing a bill to legalize and regulate psychedelics nationwide to give people an alternative treatment option for serious mental health conditions. At an Intercultural Forum on Entheogenic Medicine that took…
Read
Random Post

How to Engage with Gen Z in 2023

The beginning of the legal cannabis industry was defined by excess, and in response, the market catered to the most obvious group that had never shied away from consumption: the Cheeches, Chongs, Snoop Doggs, and Seth Rogans of the world. In…
Read
Random Post

Cookies Founder Berner Offers Advice For Cannabis Entrepreneurs

Berner is a boss. As the founder and CEO of Cookies, he’s built the world’s first billion-dollar cannabis empire. The Cookies lifestyle brand launched in the Bay Area in 2010 and grew into dispensary storefronts by 2018. As a legacy cultivator, Berner’s…
Read
Random Post

FDA’s inaction on CBD regulations means more marijuana questions for Congress

The U.S. Food and Drug Administration’s announcement Thursday that it won’t regulate products containing CBD and will instead pass that buck to Congress means the preservation of the current, uneasy status quo for now. It will also mean more work…
Read